Work

PCN126 – What is the Most Cost-Effective Strategy for Treating Chronic Myeloid Leukemia After Imatinib Loses Patent Exclusivity in Europe?

Year: 2014

Type: conference-abstract

Authors: William V. Padula, Rena M. Conti, Richard A. Larson

Language: English

Topic: Pharmaceutical Economics and Policy

Subfield: Economics and Econometrics

Field: Economics, Econometrics and Finance

Domain: Social Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W3021188215

Cites:

Cited by:

Related to: 10